Revenio Group Oyj (HEL:REG1V), a health technology company focussing on ophthalmic products, announced on Monday that it has appointed Mikko Moilanen as the CEO of the company, effective on 5 August 2019.
Timo Hildén, the previous CEO, will continue to lead the integration work of CenterVue acquisition.
Previously, Moilanen was the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, He also held the position of CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
Revenio Group consists of Icare Finland Oy, Icare USA Inc, Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business